News
-
-
COMMUNIQUÉ DE PRESSE
Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders
Transgene to participate in upcoming meetings with biotech industry leaders to discuss positive clinical data on neoantigen cancer vaccine TG4050 and present innovative immunotherapies. Learn more at www.transgene.com -
-
-
COMMUNIQUÉ DE PRESSE
Transgene et NEC présentent une survie sans récidive durable, accompagnée d’une réponse cellulaire T persistante à 24 mois avec le vaccin thérapeutique individualisé TG4050
Transgene et NEC présentent des données positives de TG4050, vaccin thérapeutique individualisé contre le cancer, avec réponse cellulaire T persistante et survie sans récidive à 24 mois lors de l'ASCO 2025 -
COMMUNIQUÉ DE PRESSE
Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccine TG4050
Transgene and NEC reveal positive data on TG4050 cancer vaccine, demonstrating durable disease-free survival and sustained T cell responses at 24 months in HPV-negative head and neck cancer. Conference call on June 6, 2025 -
-
-
COMMUNIQUÉ DE PRESSE
Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025
Transgene to present 24-month disease-free survival data from all patients in Phase I part of trial of individualized cancer vaccine, TG4050, at ASCO 2025 -
